Biotech firm Roivant Sciences raises $200 million in a funding round
Date: 2018-11-19   Author: Ojaswita Kutepatil  Category: #news

Biotech firm Roivant Sciences raises $200 million in a funding round

Roivant Sciences, a Swiss company developing innovative drugs across a wide variety of therapeutic areas, and with backing from Japan’s SoftBank, has recently announced that it has raised USD 200 million in equity investment. Reportedly, the investment round has given the company a whopping valuation of USD 7 billion.

Citing sources familiar with the matter, most of the funding came from new financiers RTW Investments and NovaQuest Capital Management among others. They further claim that the drug maker made it to the headlines last year in August when it booked USD 1.1 billion of equity investment from the SoftBank Vision Fund.

Roivant Sciences, for the record is a part of a family of companies that was started by hedge fund manager and entrepreneur Vivek Ramaswamy, who has also founded a public trading firm Axovant Sciences. The company has several subsidiaries, including Myovant and Enzyvant, and are collectively referred as the Vants.

Since SoftBanks’ financing last year, reports reveal that the number of Vants has taken a major jump from six to fourteen, and the number of employees has surged from nearly 350 to over 750.

According to reports, the company is currently anticipating topline data from six Phase III trials scheduled for next year. The product candidates include vibegron, for overactive bladder & IBS-associated pain; relugolix, for endometriosis, uterine fibroids, and prostate cancer; derazantinib, for intrahepatic cholangiocarcinoma; and lefamulin, for community-acquired bacterial pneumonia; among others.

Several other products are reported to be in preclinical, Phase I, and Phase II development, and Roivant Sciences’ subsidiary Enzyvant has also filed for FDA approval for another RVT-802. The company, in total has over 30 investigational drugs around 14 therapeutics areas.

Roivant Sciences and its Vants have now raised over USD 3 billion altogether. Despite a bumpy couple of years, the four-year old company isn’t stopping financiers from slipping money.



About Author


Ojaswita Kutepatil

Ojaswita Kutepatil

Ojaswita Kutepatil, a mechanical engineer by qualification, worked as a BDE and Technical Engineer before switching her profession to content writing. Currently, she works at AlgosOnline. as an Content writer, where she pens down write-ups pertaining to the market res...

Read More

More from Ojaswita


Post Recommendents

Panasonic stops some component shipments to Huawei amid US ban
Author: Paroma Bhattacharya

The U.S. has recently lessened the restrictions on Huawei temporarily to reduce disruption for customers.

Japan-based Panasonic Corporation has reportedly announ...


Food/Pharmaceutical Peony Market Size - Industry Analysis, Share, Growth, Trends, and Forecast 2019-2025
Author: Partha Ray

MarketStudyReport.com presents the Food/Pharmaceutical Peony Market report that provides a detailed overview of major drivers, restraints, challenges, opportunities, current industry trends and strategies impacting the global market along with est...


Oilfield Service Market Size, Development, Key Opportunity, Application and Forecast to 2025
Author: Partha Ray

This report on Oilfield Service market Added by Market Study Report, LLC, covers valuable insights based on market valuation, market size, revenue forecast, SWOT Analysis and regional outlook of this industry. The research also presents a precise ...